Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00243555
Other study ID # 2002H05183
Secondary ID FP-2005-25
Status Recruiting
Phase N/A
First received October 20, 2005
Last updated January 31, 2007
Start date September 2002

Study information

Verified date September 2006
Source McMaster University
Contact Andrea Marin, MD
Phone 905-521-2100
Is FDA regulated No
Health authority Canada: Health Canada
Study type Observational

Clinical Trial Summary

The purpose of this study is to develop a tool to better predict clinical allergy to peanut, so that those who are skin test positive but non allergic will not have to unnecessarily avoid peanut, and those with true allergy can be diagnosed, possibly without oral ingestion challenge, and treated appropriately


Description:

Peanut allergy occurs in about 1% of the population. Allergic reactions to peanuts and tree nuts account for the majority of fatal and near fatal food allergic reactions. Currently the only available treatment is complete avoidance of peanut. Despite avoidance, the majority of peanut allergic people will accidentally ingest peanut. Accurate diagnosis is critical, yet often problematic. Current diagnostic methods such as skin and blood tests cannot predict definitively who is allergic and can result in patients being falsely labeled. One such group is children who have never been exposed to peanut as a means of preventing allergy, yet have positive skin tests. The only means of definitively diagnosing this group is with an oral peanut challenge, a potentially risky procedure. Previous studies have demonstrated differences in certain genes and growth factors between peanut allergic and non-allergic individuals. The proposed study has 2 phases. The first phase, almost completed, examines expression of genes and growth factors in defined groups of peanut allergic and non-allergic individuals which should help distinguish between these groups. Peripheral blood mononuclear cells from each patient will be cultured and analyzed for a variety of growth factors and other immune molecules, including mRNA, thought to be important in allergy.

The second phase of this study will involve feeding peanut to individuals with positive skin tests, who have never been peanut exposed. Their blood will be examined before and after the challenge using information from Part 1, and results will be correlated with their ability to tolerate peanut on feeding. This study should enable us to better predict who is truly peanut allergic.

There are four groups of patients in this study. Group 1 consists of individuals who are allergic to peanut. This group of individuals will have a positive skin test to peanut and a previous allergi reaction to peanut. Group 2 consists of indivduals who have a positive skin test to peanut but who are able to ingest peanuts without problems. Group 3 consists of individuals who have a positive skin test to peanut but who have no known ingestion of peanut and who have avoided peanut lifelong for whatever reason (e.g. a strong family history of peanut allergy). Lastly, group 4 consists of control subjects who are negative to the peanut skin test and are able to tolerate peanut without problems.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 5 Years and older
Eligibility Inclusion Criteria:

- 5 years of age and older

- Informed consent (Subject has provided an appropriately signed and dated informed consent. An appropriately signed and dated assent must be obtained from the parents or guardian if the subject is a child under 18 years of age.)

- Free of any clinically significant disease, such as uncontrolled asthma, which may interfere with study evaluations

Group 1:

- skin test positive to peanut

- documented clinical history of peanut allergy. A documented clinical history may include symptoms such as hives,swelling of the mouth or tongue, throat closing sensation, shortness of breath, wheezing, lightheadedness, anaphylaxis.

Group 2:

- Positive skin test to peanut

- History of being able to tolerate peanut exposure without problems

Group 3:

- Positive skin test to peanut

- No known ingestion of peanut

Group 4:

- Negative skin test to peanut

- Negative skin test to other food and environmental allergens

- Able to tolerate peanut exposure without problems

Exclusion Criteria:

- Women who are pregnant or nursing

- use of antihistamines or decongestant therapy four days prior to clinic visit

- use of nasal or inhaled corticosteroid in the 1 month period prior to clinic visit

- use of non-steroidal anti-inflammatory drugs (NSAIDS) in the week prior to clinic visit

- Moderate or severe/ uncontrolled asthma (defined as the use of more than 4 puffs of ventolin per day, not including prophylactic medications prior to exercise)

- Symptomatic allergic rhinitis

- Patients who had an acute allergic reaction to food, drugs, and bee sting in the 1 month period prior to clinic visit

- Use of an epi-pen during the past month

- respiratory infection one month prior to clinic visit

- immunotherapy

Study Design

Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


Intervention

Procedure:
allergy skin testing

venepuncture


Locations

Country Name City State
Canada Hamilton Health Sciences Corporation, McMaster Site Hamilton Ontario

Sponsors (3)

Lead Sponsor Collaborator
Hamilton Health Sciences Corporation AllerGen NCE Inc., Food Allergy Initiative

Country where clinical trial is conducted

Canada, 

References & Publications (7)

Heaton T, Rowe J, Turner S, Aalberse RC, de Klerk N, Suriyaarachchi D, Serralha M, Holt BJ, Hollams E, Yerkovich S, Holt K, Sly PD, Goldblatt J, Le Souef P, Holt PG. An immunoepidemiological approach to asthma: identification of in-vitro T-cell response patterns associated with different wheezing phenotypes in children. Lancet. 2005 Jan 8-14;365(9454):142-9. — View Citation

Kagan RS, Joseph L, Dufresne C, Gray-Donald K, Turnbull E, Pierre YS, Clarke AE. Prevalence of peanut allergy in primary-school children in Montreal, Canada. J Allergy Clin Immunol. 2003 Dec;112(6):1223-8. — View Citation

Roberts G, Lack G. Diagnosing peanut allergy with skin prick and specific IgE testing. J Allergy Clin Immunol. 2005 Jun;115(6):1291-6. — View Citation

Sampson HA. Update on food allergy. J Allergy Clin Immunol. 2004 May;113(5):805-19; quiz 820. Review. — View Citation

Turcanu V, Maleki SJ, Lack G. Characterization of lymphocyte responses to peanuts in normal children, peanut-allergic children, and allergic children who acquired tolerance to peanuts. J Clin Invest. 2003 Apr;111(7):1065-72. — View Citation

Umetsu DT. Revising the immunological theories of asthma and allergy. Lancet. 2005 Jan 8-14;365(9454):98-100. — View Citation

van Odijk J, Ahlstedt S, Bengtsson U, Borres MP, Hulthén L. Double-blind placebo-controlled challenges for peanut allergy the efficiency of blinding procedures and the allergenic activity of peanut availability in the recipes. Allergy. 2005 May;60(5):602-5. — View Citation

See also
  Status Clinical Trial Phase
Completed NCT01904604 - Peanut Epicutaneous Phase II Immunotherapy Clinical Trial Phase 2
Recruiting NCT01429896 - The Effect of Extrinsic Factors on Food Allergy Phase 2
Completed NCT00850668 - Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults Phase 1
Active, not recruiting NCT04090203 - Boiled Peanut Oral Immunotherapy Phase 1
Completed NCT00382148 - A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g Phase 2
Completed NCT01084174 - A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy Phase 1/Phase 2
Recruiting NCT05695261 - Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients Phase 2
Completed NCT01373242 - Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance Phase 1/Phase 2
Completed NCT02424136 - PEAnut Anaphylaxis Predictors N/A
Completed NCT00932282 - Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy Phase 1/Phase 2
Completed NCT00356174 - An Observational Study of Childhood Food Allergy N/A
Completed NCT02304991 - FARE Peanut SLIT and Early Tolerance Induction Phase 2
Recruiting NCT05621317 - A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy Phase 2
Recruiting NCT03679676 - Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE) Phase 2
Completed NCT00580606 - A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial Phase 1/Phase 2
Completed NCT02665793 - Mechanisms Underlying Peanut Allergic Reactions in TRACE Peanut Study Participants: Extension Study N/A
Completed NCT01867671 - Peanut Oral Immunotherapy in Children Phase 2
Active, not recruiting NCT03937726 - Boiled Peanut Immunotherapy for the Treatment of Peanut Allergy N/A
Completed NCT00815035 - Oral Immunotherapy (OIT) for Peanut Allergy Phase 2
Completed NCT01891136 - Oral Peanut Immunotherapy for Peanut Allergic Patients Phase 0